Items where Author is "Ferris, Robert L"

Article

Kansy, Benjamin A and Lin, Yan and Ding, Fei and Gibson, Sandra Poveda and Jie, Hyun-Bae and Ferris, Robert L (2015) Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment. Journal for ImmunoTherapy of Cancer, 3 (S2).

Trivedi, Sumita and Srivastava, Raghvendra M and Concha-Benavente, Fernando and Garcia-Bates, Tatiana M and Li, Jing and Ferris, Robert L (2015) Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients. Journal for ImmunoTherapy of Cancer, 3 (S2).

Srivastava, Raghvendra M and Clump, David A and Ferris, Robert L (2015) Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model. Journal for ImmunoTherapy of Cancer, 3 (S2).

Kansy, Benjamin A and Srivastava, Raghvendra M and Jie, Hyun-Bae and Shayan, Gulidanna and Lei, Yu and Li, Jing and Gooding, William and Brandau, Sven and Lang, Stephan and Schmitt, Nicole and Freeman, Gordon J and Clump, David A and Ferris, Robert L (2015) Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model. Journal for ImmunoTherapy of Cancer, 3 (S2).

Concha-Benavente, Fernando and Srivastava, Raghvendra M and Kansy, Benjamin and Ferris, Robert L (2015) PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer. Journal for ImmunoTherapy of Cancer, 3 (S2).

Ferris, Robert L and Even, Caroline and Haddad, Robert and Tahara, Makoto and Goswami, Trishna and Franks, April and Emeribe, Ugochi and Jarkowski, Anthony and Melillo, Giovanni and Licitra, Lisa (2015) Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle. Journal for ImmunoTherapy of Cancer, 3 (S2).

Shayan, Gulidanna and Ferris, Robert L (2015) PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL. Journal for ImmunoTherapy of Cancer, 3 (Suppl ). P196 - P196. ISSN 2051-1426

Ferris, Robert L and Kansy, Benjamin A and Gibson, Sandra and Srivastava, Raghvendra M and Bryan, James and Hershberg, Robert M (2015) A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC). Journal for ImmunoTherapy of Cancer, 3 (Suppl ). P144 - P144. ISSN 2051-1426

Li, Jing and Ferris, Robert L (2014) Differential expression of PD-1 and Tim-3 marks activation versus exhaustion status of T cells in the tumor microenvironment. Journal for ImmunoTherapy of Cancer, 2 (S3).

Concha-Benavente, Fernando and Ferris, Robert L (2014) IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells. Journal for ImmunoTherapy of Cancer, 2 (S3).

Li, Jing and Ferris, Robert L (2014) PD-1/SHP-2 negatively regulate Tc1/Th1 phenotypic responses and activation of T cells in the tumor microenvironment. Journal for ImmunoTherapy of Cancer, 2 (S3).

Ferris, Robert L and Cohen, Ezra and Gash, Kelly and Whiting, Sam and Manjarrez, Kristi and Dietsch, Greg and Hershberg, Robert and Bryan, James (2014) Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Journal for ImmunoTherapy of Cancer, 2 (Suppl ). P69 - P69. ISSN 2051-1426

Srivastava, Raghvendra M and Jie, Hyun-bae and Ferrone, Soldano and Ferris, Robert L (2013) STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients. Journal for ImmunoTherapy of Cancer, 1 (S1).

Jie, Hyun-Bae and Li, Jing and Srivastava, Raghvendra and Ferris, Robert L (2013) TIM-3+ T cells are not exhausted but activated cells in the tumor microenvironment. Journal for ImmunoTherapy of Cancer, 1 (S1).